What’s pharma doing wrong to improve trial diversity? ‘Everything’

Pharma’s missing the mark when it comes to recruiting Black patients, and Ricki Fairley, CEO of The Black Breast Cancer Alliance, reveals what’s needed.

By Karissa Waddick • April 12, 2023

Woman of the Week: uMotif’s Julia Lakeland

The chief product officer’s work in transforming clinical trial technology is driven by people.

By Taren Grom • April 12, 2023

Explore the Trendline➔

Oncology R&D

Cancer research remains a prime focus for the industry and often leads to pharma’s most impactful breakthroughs.   

By PharmaVoice staff

Where one unicorn struggled, another biotech is aiming for a diabetes win

Intarcia looked poised to break into a lucrative diabetes implant market but has been dogged by safety issues — now Vivani thinks it’s found a way to succeed.

By Kelly Bilodeau • April 10, 2023

Despite J&J’s exit, Big Pharma is closing in on a launch of the first RSV vax this year

Although Janssen bowed out of the RSV vaccine race, several pharmas are quickly closing in on the finish line in a disease with decades of unmet need.

By Michael Gibney • April 6, 2023

Woman of the Week: Intergalactic Therapeutics’ Dr. Theresa Heah

Welcome to the Woman of the Week podcast, a weekly discussion that illuminates the unique stories of women leaders who are catalyzing change throughout the life sciences industry. You can check out all our podcast episodes here. Dr. Theresa Heah has spent her entire career moving ophthalm...

By Taren Grom • April 5, 2023

Amgen’s aim for a ‘moonshot’ in cardiovascular disease

A VP of global development at Amgen explains how treating general medicine diseases could one day resemble approaches in oncology.  

By Taren Grom • April 5, 2023

Moderna exec: ‘There is nothing but global health’

How Chantal Friebertshäuser is helping lead Moderna’s plan to expand its global reach.  

By Alexandra Pecci • April 4, 2023

All eyes turn to Karuna as it aims for an approval of a would-be blockbuster

In the red-hot race for new schizophrenia treatments, Karuna Therapeutics is close to an FDA submission.

By Kelly Bilodeau • April 3, 2023

Digital biomarkers lay the groundwork for precision medicine beyond the bloodwork

Biomarkers are the hidden talent behind precision medicine, and finding them doesn't have to always come from a blood test — digital pioneers are finding another way.

By Michael Gibney • March 30, 2023

Predator and prey: Harnessing phages to fight antibiotic resistance

Phages, bacteria’s natural predator, could help combat the growing threat of superbugs. But can these therapies rise above antibiotic market woes?

By Karissa Waddick • March 30, 2023

Woman of the Week: Psilera’s Jackie von Salm

Psilera founder’s “third eye” approach to psychedelics ushers them into the therapeutic realm.

By Taren Grom • March 29, 2023

How one of the world’s sharpest inventors keeps the ideas coming. Hint: It’s not at work

Steve Quake, head of science for the Chan Zuckerberg Initiative, who’s had several “once-in-a-lifetime” ideas, provides advice on how to find inspiration.

By Alexandra Pecci • March 27, 2023

What would you fix with a ‘magic wand?’ Pharma leaders chime in about clinical trials

How life science execs would transform clinical trials with a little hocus pocus.

By PharmaVoice staff • March 24, 2023

Everyone says they’re patient-centric, but have they really walked the walk?

Life science leaders provide practical tips on how to create a sustainable patient-focused culture.

By Karissa Waddick • March 23, 2023

This GSK clinical data leader embraces the ‘Rubik’s cube’ problem: solving for all sides at once

The clinical data space is rapidly changing the face of the industry, GSK's Mayank Anand said — and the way organizations adopt technology is a critical part of the equation.

By Michael Gibney • March 23, 2023

Woman of the Week: RIGImmune’s Susan Sobolov

RIGImmune’s president is setting her sights on an off-the-shelf viral vaccine.

By Taren Grom • March 22, 2023

Viral roots: A look at how modern outbreaks began

As experts wrestle with COVID-19’s lab leak versus animal market debate, here’s what experts say are the suspected origins for some of the worst viral outbreaks in the last century.

By Meagan Parrish • March 22, 2023

Making the leap from the lab to the boardroom

Four academics-turned-executives share what they’ve learned about the pivot point between life sciences academia and entrepreneurship.

By Alexandra Pecci • March 21, 2023

‘The Last of Us’ might be fiction, but fungi are a looming threat

Fungal infections are a growing challenge for hospitalized patients, and new treatments are badly needed.

By Kelly Bilodeau • March 20, 2023

This biotech’s ‘Microsoft’ approach could change how we see gene therapy

The company’s using a unique component-based platform to develop functional cures for diseases, including HIV.

By Karissa Waddick • March 20, 2023

A biopharma CEO’s quest for global health equity has put him in the running for a Nobel Prize

Dr. Ryan Saadi, CEO of Tevogen Bio, is making good on a lifelong goal of bringing T cell therapies to people who need them.

By Taren Grom • March 17, 2023

Woman of the Week: Novartis Gene Therapies’ Chris Fox

Welcome to the Woman of the Week podcast, a weekly discussion that illuminates the unique stories of women leaders who are catalyzing change throughout the life sciences industry. You can check out all our podcast episodes here. When Novartis acquired AveXis and its spinal muscular atroph...

By Taren Grom • March 15, 2023

The PharmaVoice 100 — Who makes the cut

What we’re looking for in each new class of honorees.

By Meagan Parrish • March 15, 2023

The power of connections for a startup CEO

Priyanka Dutta-Passecker, head of wound-care specialist Healiva, discusses the importance of tapping her network in starting and running a biotech.

By Alexandra Pecci • March 14, 2023

Babson aims to shed Theranos curse with new blood testing tech

Babson Diagnostics is trying to create a less invasive blood testing technology — can it gain trust in the post-Theranos era?

By Kelly Bilodeau • March 13, 2023